Product Description: Lomedeucitinib (BMS-986322) is act by targeting receptor tyrosine protein kinase (TYK2). Lomedeucitinib can be used for the research of plaque psoriasis[1].
Applications: COVID-19-immunoregulation
Formula: C18H17D3N6O4S
References: [1]Lomedeucitinib by Bristol-Myers Squibb for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval.